Pancreatic Cancer Research

ResearcherRutgers, The State Univ Of N.J.Active in the last 2 years

Darren R. Carpizo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3824-0160; OpenAlex author ID A5012134377; NIH RePORTER profile ID 9842498. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 7)
Trials
1 (principal investigator on 1)
Grants
6
Labs led
2
Collaborators
80
Papers, trials and grants by year

2012: 1 trial · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 grant · 2017: 1 paper, 1 grant · 2018: 1 paper, 1 grant · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers, 3 grants

Papers 15

  1. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Last author DOI 10.1016/j.devcel.2026.04.001↗
  2. UNC5B regulates epithelial-to-mesenchymal transition through a SRC-ZEB1 signaling axis to facilitate pancreatic cancer metastasis. Last author DOI 10.1038/s41388-026-03908-4↗
  3. Protocol for isolating extracellular vesicles from pancreatic cancer cells for liver metastatic niche research. Last author DOI 10.1016/j.xpro.2024.103256↗
  4. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Last author DOI 10.1016/j.celrep.2023.113369↗
  5. Tumor microbiome links cellular programs and immunity in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.09.009↗
  6. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  7. The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12497-x↗
  8. ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer. First author DOI 10.1245/s10434-022-12541-w↗
  9. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  10. Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database. Last author DOI 10.1089/pancan.2019.0017↗
  11. A Novel Model of Pancreatic Cancer Dormancy Reveals Mechanistic Insights and a Dormancy Gene Signature with Human Relevance Last author DOI 10.1101/2020.04.13.037374↗
  12. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Co-author DOI 10.21037/apc.2018.07.05↗
  13. U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts. Last author DOI 10.1158/1535-7163.mct-16-0867↗
  14. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Co-author DOI 10.1101/gad.264861.115↗
  15. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Co-author DOI 10.18632/oncotarget.4126↗

Trials 1

  1. A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Principal investigator NCT01694589↗

Grants 6

  1. Genetics, Epigenetics and Metabolism Research Program P30CA272302↗
  2. Targeting Intrinsic and Extrinsic Barriers to Treat Metastatic Pancreatic Cancer R01CA295861↗
  3. The role of circadian gene regulation in pancreatic cancer progression and immune evasion U01CA313692↗
  4. Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer AWARD pancan:2018-darren-carpizo-md-phd-investigating-netrin-1-as-a-new-therapeu
  5. Exploration of a Mutant p53 Reactivating Compound K08CA172676↗
  6. Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer R21CA191622↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paula M. Vertino · 2 shared papers, 2 shared grants, 2020–2026 · strength 2.16
  2. Scott Andrew Gerber · 1 shared grant, 2026 · strength 1.26
  3. Brian James Altman · 1 shared paper, 1 shared grant, 2026 · strength 1.20
  4. Jonathan W Friedberg · 1 shared grant, 2026 · strength 0.86
  5. Laura Maria Calvi · 1 shared grant, 2026 · strength 0.86
  6. Anthony Casabianca · 5 shared papers, 2020–2026 · strength 0.77
  7. Crissy Dudgeon · 6 shared papers, 2015–2026 · strength 0.73
  8. Mihir Maheshkumar Shah · 5 shared papers, 2018–2022 · strength 0.68
  9. Subhajyoti De · 4 shared papers, 2020–2026 · strength 0.61
  10. Muhammad Sadeqi Nezhad · 2 shared papers, 2024–2026 · strength 0.44
  11. Alexa D. Melucci · 2 shared papers, 2022 · strength 0.41
  12. Aram F. Hezel · 2 shared papers, 2023–2026 · strength 0.39
  13. Patrick Mehlen · 2 shared papers, 2023–2024 · strength 0.33
  14. Igor A. Astsaturov · 2 shared papers, 2023–2024 · strength 0.33
  15. Bassel Ghaddar · 2 shared papers, 2020–2022 · strength 0.27
  16. Stephano S. Mello · 1 shared paper, 2026 · strength 0.25
  17. Samuel I Gunderson · 1 shared grant, 2016 · strength 0.25
  18. Lan Wang · 1 shared paper, 2026 · strength 0.20
  19. Anna Bianchi · 1 shared paper, 2026 · strength 0.20
  20. Jean L. Grem · 1 shared paper, 2026 · strength 0.20
  21. Michael Anthony Hollingsworth · 1 shared paper, 2026 · strength 0.20
  22. Paul M. Grandgenett · 1 shared paper, 2026 · strength 0.20
  23. Brian B. Haab · 1 shared paper, 2026 · strength 0.20
  24. Jashodeep Datta · 1 shared paper, 2026 · strength 0.20
  25. Salma K. Jabbour · 2 shared papers, 2018–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.